Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy

PURPOSE: Patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer can benefit from trastuzumab deruxtecan. Given the unclear prognostic characteristics of HER2-low breast cancer, we investigated the prognostic characteristics of HER2-low expression from primary tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Youzhao, Zhu, Mingda, Zhang, Jingyang, Lv, Minhao, Chen, Xiuchun, Liu, Zhenzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582545/
https://www.ncbi.nlm.nih.gov/pubmed/37024094
http://dx.doi.org/10.4143/crt.2022.1633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582545/
https://www.ncbi.nlm.nih.gov/pubmed/37024094
http://dx.doi.org/10.4143/crt.2022.1633

Ejemplares similares